Tivantinib is a selective small molecular inhibitor of cellular mesenchymal-epithelial transcription factor (c-Met or MET) that was clinically developed in various cancers, including non-small-cell lung cancer (9), colon cancer (10), gastric cancer (11), and HCC (12). The gene discussed is MET; the disease is cancer.